Novo Nordisk's (NVO) stock was up more than 12% in pre-market trading Friday on news the company's latest weight loss product ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

The latest glucagon-like peptide 1 (GLP-1) receptor agonists have been heralded for their potential to not only boost weight loss and glucose ... tirzepatide, and new GLP-1 drugs in the research ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Weight loss drugs catapulted many into a new wellness era ... of new drugs looking to enter the market. Between August 2021 and August 2023, the prevalence of obesity among adults was 40.3 ...

The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs ... of a new Medicare initiative aimed at lowering prescription drug prices ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on the body, researchers say. The analysis, involving about two million ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product ...